News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
132,167 Results
Type
Article (7645)
Company Profile (57)
Press Release (124462)
Multimedia
Podcasts (22)
Webinars (5)
Section
Business (38719)
Career Advice (89)
Deals (6046)
Drug Delivery (10)
Drug Development (23961)
Employer Resources (12)
FDA (3091)
Job Trends (3597)
News (69698)
Policy (4655)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (328)
Accelerated approval (12)
Adcomms (13)
Allergies (3)
Alliances (11325)
ALS (22)
Alzheimer's disease (164)
Antibody-drug conjugate (ADC) (252)
Approvals (3249)
Artificial intelligence (174)
Autoimmune disease (54)
Automation (5)
Bankruptcy (55)
Best Places to Work (3304)
BIOSECURE Act (1)
Biosimilars (89)
Biotechnology (50)
Bladder cancer (126)
Brain cancer (47)
Breast cancer (488)
Cancer (3516)
Cardiovascular disease (36)
Career advice (82)
Career pathing (5)
CAR-T (126)
CDC (3)
Cell therapy (267)
Cervical cancer (18)
Clinical research (21381)
Collaboration (685)
Company closure (2)
Compensation (215)
Complete response letters (10)
COVID-19 (352)
CRISPR (26)
C-suite (290)
Cystic fibrosis (9)
Data (2260)
Decentralized trials (1)
Denatured (4)
Depression (11)
Diabetes (38)
Diagnostics (1405)
Digital health (8)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (98)
Drug pricing (25)
Drug shortages (1)
Duchenne muscular dystrophy (27)
Earnings (14137)
Editorial (12)
Employer branding (2)
Employer resources (13)
Events (25071)
Executive appointments (316)
FDA (3934)
Fibrodysplasia Ossificans Progressiva (3)
Frontotemporal dementia (2)
Funding (330)
Gene editing (44)
Generative AI (17)
Gene therapy (91)
GLP-1 (127)
Government (488)
Guidances (87)
Healthcare (4066)
HIV (8)
Huntington's disease (3)
IgA nephropathy (17)
Immunology and inflammation (70)
Immuno-oncology (60)
Indications (55)
Infectious disease (392)
Inflammatory bowel disease (35)
Inflation Reduction Act (3)
Influenza (15)
Intellectual property (57)
Interviews (12)
IPO (3010)
IRA (8)
Job creations (490)
Job search strategy (70)
JPM (25)
Kidney cancer (17)
Labor market (9)
Layoffs (140)
Leadership (6)
Legal (482)
Liver cancer (48)
Longevity (1)
Lung cancer (522)
Lymphoma (226)
Machine learning (14)
Management (3)
Manufacturing (135)
MASH (6)
Medical device (878)
Medtech (883)
Mergers & acquisitions (3293)
Metabolic disorders (106)
Multiple sclerosis (15)
NASH (1)
Neurodegenerative disease (30)
Neuropsychiatric disorders (9)
Neuroscience (323)
NextGen: Class of 2026 (956)
Non-profit (507)
Now hiring (18)
Obesity (60)
Opinion (38)
Ovarian cancer (132)
Pain (27)
Pancreatic cancer (168)
Parkinson's disease (32)
Partnered (1)
Patents (93)
Patient recruitment (160)
Peanut (2)
People (13541)
Pharmaceutical (12)
Pharmacy benefit managers (3)
Phase 1 (8057)
Phase 2 (8931)
Phase 3 (6895)
Pipeline (1685)
Policy (33)
Postmarket research (481)
Preclinical (2540)
Press Release (2)
Prostate cancer (170)
Psychedelics (4)
Radiopharmaceuticals (188)
Rare diseases (147)
Real estate (753)
Recruiting (5)
Regulatory (4805)
Reports (8)
Research institute (696)
Resumes & cover letters (11)
RNA editing (2)
RSV (10)
Schizophrenia (37)
Series A (65)
Series B (30)
Service/supplier (1)
Sickle cell disease (37)
Special edition (3)
Spinal muscular atrophy (16)
Sponsored (6)
Startups (767)
State (1)
Stomach cancer (12)
Supply chain (12)
Tariffs (8)
The Weekly (18)
Vaccines (189)
Venture capital (34)
Weight loss (25)
Women's health (6)
Date
Last 7 days (154)
Last 30 days (525)
Last 365 days (8369)
2026 (957)
2025 (8426)
2024 (9498)
2023 (10641)
2022 (13116)
2021 (13196)
2020 (11011)
2019 (8646)
2018 (6379)
2017 (7170)
2016 (6332)
2015 (7019)
2014 (4605)
2013 (3156)
2012 (3397)
2011 (3403)
2010 (3104)
Location
Africa (88)
Alabama (19)
Alaska (1)
Arizona (25)
Arkansas (2)
Asia (11413)
Australia (1541)
California (3145)
Canada (707)
China (597)
Colorado (82)
Connecticut (131)
Delaware (241)
Europe (20857)
Florida (411)
Georgia (12)
Idaho (6)
Illinois (329)
India (18)
Indiana (100)
Iowa (9)
Japan (208)
Kansas (10)
Kentucky (13)
Maine (4)
Maryland (336)
Massachusetts (2481)
Michigan (27)
Minnesota (111)
Missouri (12)
Montana (8)
Nebraska (2)
Nevada (10)
New Hampshire (10)
New Jersey (889)
New Mexico (3)
New York (745)
North Carolina (240)
Northern California (1668)
Ohio (66)
Oklahoma (1)
Oregon (5)
Pennsylvania (464)
Puerto Rico (3)
Rhode Island (6)
South America (118)
South Carolina (3)
Southern California (1237)
Tennessee (36)
Texas (540)
United States (10602)
Utah (75)
Virginia (26)
Washington D.C. (9)
Washington State (293)
Wisconsin (35)
132,167 Results for "alx oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ALX Oncology Announces Pricing of Underwritten Offering - January 30, 2026
February 1, 2026
·
4 min read
Press Releases
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 9, 2026
·
1 min read
Press Releases
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
January 9, 2026
·
5 min read
Press Releases
ALX Oncology to Present at Upcoming Investor Conferences
November 19, 2025
·
1 min read
Press Releases
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
February 1, 2026
·
4 min read
Press Releases
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
·
14 min read
Press Releases
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
October 24, 2025
·
5 min read
Press Releases
ALX Oncology to Participate in Upcoming Investor Conferences in September 2025
September 1, 2025
·
1 min read
Press Releases
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
August 20, 2025
·
5 min read
Press Releases
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
September 15, 2025
·
4 min read
1 of 13,217
Next
